Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript
Hi, welcome back, everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. This is the continuation of our Virtual Oncology Summit, the third day, the three-day virtual conference. It's my great pleasure to have with me from Olema Pharmaceuticals, Sean Bohen, MD, PhD, the President and CEO of the company.
Sean, thanks so much for stepping away from your day job for a few minutes, and chatting with us about Olema and the pipeline.
So maybe just to kick it off, for those listening that a little bit less familiar with Olema, maybe just walk through at a high level on what you're focused on, and then maybe if you could comment specifically on how your CERAN/SERD approach differs from some of the other approaches in the ER space that people are perhaps a little bit more familiar with, for example, the CERAN, the SERDs, and the ER degraders. So that would be a great place to kick off the conversation.
Great, great. Thank you, Yigal,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
